DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
Phone720-631-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.40 billion
Profitability
Miscellaneous
Employees77,700
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) released its earnings results on Thursday, August, 1st. The company reported $1.22 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.10 by $0.12. The business had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.86 billion. Davita had a net margin of 1.21% and a return on equity of 14.67%. The business's revenue was down 1.5% on a year-over-year basis. During the same period last year, the company posted $1.05 EPS. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
8 brokers have issued 12-month price targets for Davita's shares. Their predictions range from $60.00 to $70.00. On average, they expect Davita's stock price to reach $65.35 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for Davita.
What is the consensus analysts' recommendation for Davita?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.
Has Davita been receiving favorable news coverage?
Media headlines about DVA stock have been trending somewhat negative on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Davita earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Davita.
Are investors shorting Davita?
Davita saw a decrease in short interest during the month of September. As of September 30th, there was short interest totalling 10,930,000 shares, a decrease of 16.8% from the August 30th total of 13,130,000 shares. Based on an average daily volume of 3,100,000 shares, the short-interest ratio is currently 3.5 days. Currently, 7.1% of the company's stock are sold short. View Davita's Current Options Chain.
Who are some of Davita's key competitors?
What other stocks do shareholders of Davita own?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 63)
- Mr. Joel Ackerman, Chief Financial Officer (Age 54)
- Mr. James K. Hilger, Chief Accounting Officer (Age 57)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)
Who are Davita's major shareholders?
Davita's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Robeco Institutional Asset Management B.V. (0.05%), Triad Investment Management (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Crossmark Global Holdings Inc. (0.02%), Nisa Investment Advisors LLC (0.02%) and Commerzbank Aktiengesellschaft FI (0.01%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which institutional investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including Triad Investment Management, State of Alaska Department of Revenue, Lau Associates LLC, Stonebridge Capital Management Inc., CenturyLink Investment Management Co, Campbell & CO Investment Adviser LLC, Meeder Asset Management Inc. and Vigilant Capital Management LLC. View Insider Buying and Selling for Davita.
Which institutional investors are buying Davita stock?
DVA stock was bought by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Zurcher Kantonalbank Zurich Cantonalbank , Nisa Investment Advisors LLC, Rothschild Investment Corp IL, Robecosam AG, Whittier Trust Co., NuWave Investment Management LLC and North Star Investment Management Corp.. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $58.69.
How big of a company is Davita?
Davita has a market capitalization of $9.41 billion and generates $11.40 billion in revenue each year. The company earns $159.39 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 77,700 workers across the globe.View Additional Information About Davita.
What is Davita's official website?
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
